

PRECISION THERAPY IN NSCLC

PHARMACIST PERSPECTIVES ON TESTING STRATEGIES AND BIOMARKER-DRIVEN TREATMENT APPROACHES

Bibliography and Suggested Reading

- Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non–small-cell lung cancer. *JAMA Oncol.* 2019;5(2):173–180.
- Arnall JR, Petro R, Patel JN, Kennedy L. A clinical pharmacy pilot within a precision medicine program for cancer patients and review of related pharmacist clinical practice. *J Oncol Pharm Pract.* 2019;25(1):179–186.
- Bauml J, Levy B. Clonal hematopoiesis: a new layer in the liquid biopsy story in lung cancer. *Clin Cancer Res.* 2018;24(18):4352–4354.
- Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non–small-cell lung cancer in the global phase III ALEX Study [published correction appears in: *J Thorac Oncol.* 2019;14(11):2023]. *J Thorac Oncol.* 2019;14(7):1233–1243.
- Doebele R, Paz-Ares L, Farago AF, et al. Entrectinib in *NTRK*-fusion positive (*NTRK*-FP) non–small-cell lung cancer (NSCLC): integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001). Abstract CT131. Presented at: the American Association for Cancer Research Annual Meeting; March 29–April 3, 2019; Atlanta, Georgia.
- Drilon A, Barlesi F, De Braud F, et al. Entrectinib in locally advanced or metastatic *ROS1* fusion-positive non–small-cell lung cancer (NSCLC): integrated analysis of ALKA-371-001, STARTRK-1, and STARTRK-2. Abstract CT192. Presented at: American Association for Cancer Research Annual Meeting; March 29–April 3, 2019; Atlanta, Georgia.
- Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a *MET* exon 14 alteration. *Nat Med.* 2020;26(1):47–51.
- Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in *TRK* fusion-positive cancers in adults and children. *N Engl J Med.* 2018;378(8):731–739.
- Drilon A, Oxnard G, Wirth L, et al. Registrational results of LIBRETTO-001: a phase 1/2 trial of loxo-292 in patients with *RET* fusion-positive lung cancers. Abstract PL02-88. Presented at: 2019 World Conference on Lung Cancer; September 7–10, 2019; Barcelona, Spain.
- Drilon A, Zhai D, Deng W, et al. Repotrectinib, a next generation *TRK* inhibitor, overcomes *TRK* resistance mutations including solvent front, gatekeeper and compound mutations. Abstract 442. Presented at: American Association for Cancer Research Annual Meeting; March 29–April 3, 2019; Atlanta, Georgia.
- Fukuoka M, Wu Yi-Long, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in asia (IPASS). *J Clin Oncol.* 2011;29:2866-2874.
- Gadgeel S, Peters S, Mok T, et al. Alectinib vs crizotinib in treatment-naïve ALK+ NSCLC: CNS efficacy results from the ALEX study. Abstract 12980_PR. Presented at: European Society for Medical Oncology 2017 Congress; September 11, 2017; Madrid, Spain.
- Gainor JF, Lee DH, Curigliano G, et al. Clinical activity and tolerability of BLU-667, a highly potent and selective *RET* inhibitor, in patients (pts) with advanced *RET*-fusion+ non–small-cell lung cancer (NSCLC). Abstract 9008. Presented at: ASCO Annual Meeting 2019; June 3, 2019; Chicago, Illinois. *J Clin Oncol.* 2019;37(15_suppl):9008.
- Husain H, Velculescu VE. Cancer DNA in the circulation: the liquid biopsy. *JAMA.* 2017;318(13):1272–1274.
- Johnsen JM, Nickerson DA, Reiner AP. Massively parallel sequencing: the new frontier of hematologic genomics. *Blood.* 2013;122(19):3268–3275.

PRECISION THERAPY IN NSCLC

PHARMACIST PERSPECTIVES ON TESTING STRATEGIES AND BIOMARKER-DRIVEN TREATMENT APPROACHES

- Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline update. *J Clin Oncol*. 2018;36(9):911–919.
- Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer [published correction appears in: *N Engl J Med*. 2011;364(6):588]. *N Engl J Med*. 2010;363(18):1693–1703.
- Lan S, Shun L. Crizotinib versus pemetrexed-based chemotherapy in patients with advanced ROS1-rearranged non–small-cell lung cancer. *J Clin Oncol*. 2019;37(15_suppl):9101–9101.
- Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non–small-cell lung cancer. *Clin Cancer Res*. 2019;25(15):4691–4700.
- Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in *EGFR*-mutated non–small-cell lung cancer. *Br J Cancer*. 2019;121(9):725–737.
- Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *J Thorac Oncol*. 2018;13:323–358.
- Lisberg A, Cummings A, Goldman JW, et al. A phase II study of pembrolizumab in *EGFR*-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. *J Thorac Oncol*. 2018;13(8):1138–1145.
- Lui C, Cady N, Batt C. Nucleic acid-based detection of bacterial pathogens using integrated microfluidic platform systems. *Sensors (Basel, Switzerland)*. 2009;9(5):3713–3744.
- McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer [published correction appears in: *JAMA Oncol*. 2016;2(1):146]. *JAMA Oncol*. 2016;2(1):46–54.
- Mok TS, Wu Y-L, Ahn M-J, et al; AURA3 Investigators. Osimertinib or platinum-pemetrexed in *EGFR* T790M–positive lung cancer. *N Engl J Med*. 2017;376(7):629–640.
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med*. 2009;361(10):947–957.
- National Comprehensive Cancer Network. NCCN guidelines: non–small-cell lung cancer. Version 3.2020. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed March 2020.
- New mechanism in the regulation of human genes. Helmholtz Zentrum Muenchen website. July 2011. <https://www.helmholtz-muenchen.de/aktuelles/uebersicht/pressemitteilungnews/article/17869/index.html>. Accessed March 2020.
- Pao W, Hutchinson KE. Chipping away at the lung cancer genome. *Nat Med*. 2012;18(3):349–351.
- Pennell NA, Arcila ME, Gandara DR, West H. Biomarker testing for patients with advanced non–small-cell lung cancer: real-world issues and tough choices. *ASCO Educational Book*. 2019;39:531–542.
- Peters S, Camidge DR, Shaw AT, et al; ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. *N Engl J Med*. 2017;377(9):829–838.
- Planchard D, Popat S, Kerr K, et al; ESMO Guidelines Committee. Metastatic non–small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018;29(Suppl_4):iv192–iv237.
- Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non–small-cell lung cancer: an open-label, phase 2 trial. *Lancet Oncol*. 2017;18(10):1307–1316.

PRECISION THERAPY IN NSCLC

PHARMACIST PERSPECTIVES ON TESTING STRATEGIES AND BIOMARKER-DRIVEN TREATMENT APPROACHES

- Ramalingam SS, Gray JE, Ohe Y, et al. Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis. *Ann Oncol*. 2019;30(Suppl_5):v851–v934.
- Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, *EGFR*-mutated advanced NSCLC. *N Engl J Med*. 2020;382(1):41–50.
- Ramalingam SS, Yang JCH, Lee CK, et al. Osimertinib as first-line treatment of *EGFR* mutation–positive advanced non–small-cell lung cancer. *J Clin Oncol*. 2018;36(9):841–849.
- Rolfo C, Mack PC, Scagliotti GV, et al. Liquid biopsy for advanced non–small-cell lung cancer (NSCLC): a statement paper from the IASLC. *J Thorac Oncol*. 2018;13(9):1248–1268.
- Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced *EGFR* mutation-positive non–small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*. 2012;13(3):239–246.
- Saadeh C, Bright D, Rustem D. Precision medicine in oncology pharmacy practice. *Acta Med Acad*. 2019;48(1):90–104.
- Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. *Ann Oncol*. 2019;30(5):839–844.
- Schoenfeld AJ, Chan JM, Kubota D, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in *EGFR*-mutant lung cancer. *Clin Cancer Res*. 2020 Jan 7. [Epub ahead of print]
- Scientists pinpoint a new cause of resistance to *EGFR*-targeting drugs. Memorial Sloan Kettering Cancer Center website. June 2018. <https://www.mskcc.org/blog/scientists-pinpoint-new-cause-resistance-egfr-targeting-drugs>. Accessed March 2020.
- Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to *EGFR* inhibitors. *Sci Transl Med*. 2011;3(75):75ra26.
- Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with *EGFR* mutations. *J Clin Oncol*. 2013;31(27):3327–3334.
- Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non–small-cell lung cancer with *ALK* or *ROS1* rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. *Lancet Oncol*. 2017;18(12):1590–1599.
- Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in *ROS1*-rearranged advanced non–small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. *Ann Oncol*. 2019;30(7):1121–1126.
- Shaw AT, Solomon BJ, Besse B, et al. *ALK* resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non–small-cell lung cancer. *J Clin Oncol*. 2019;37(16):1370–1379.
- Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced *ROS1*-positive non–small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. *Lancet Oncol*. 2019;20(12):1691–1701.
- Singal G, Miller PG, Agarwala V, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non–small-cell lung cancer using a clinicogenomic database. *JAMA*. 2019;321(14):1391–1399.
- Socinski MA, Jotte RM, Cappuzzo F, et al; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med*. 2018;378(24):2288–2301.
- Solomon BJ, Mok T, Kim DW, et al; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in *ALK*-positive lung cancer [published correction appears in: *N Engl J Med*. 2015;373(16):1582]. *N Engl J Med*. 2014;371(23):2167–2177.

PRECISION THERAPY IN NSCLC

PHARMACIST PERSPECTIVES ON TESTING STRATEGIES AND BIOMARKER-DRIVEN TREATMENT APPROACHES

- Soria JC, Ohe Y, Vansteenkiste J, et al; FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. *N Engl J Med*. 2018;378(2):113–125.
- Trivedi H, Acharya D, Chamrathy U, et al. Implementation and outcomes of a molecular tumor board at Herbert-Herman Cancer Center, Sparrow Hospital. *Acta Med Acad*. 2019;48(1):105–115.
- Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint Phase 1 Project. *J Thorac Oncol*. 2018;13(9):1302–1311.
- Types of lung cancer. Lung Cancer Foundation of American website. <https://lcfamerica.org/lung-cancer-info/types-lung-cancer/>. Accessed March 2020.
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors. Association for Molecular Pathology website. https://www.amp.org/AMP/assets/File/clinical-practice/26340_Lung%20CareInfoGrph1918_012218 AMP%20linked%20v2.pdf?pass=16. Accessed March 2020.
- Walko C, Kiel PJ, Kolesar J. Precision medicine in oncology: new practice models and roles for oncology pharmacists. *Am J Health Syst Pharm*. 2016;73(23):1935–1942.
- Xu H, Lin G, Huang C, et al. Assessment of concordance between 22C3 and SP142 immunohistochemistry assays regarding PD-L1 expression in non-small-cell lung cancer. *Sci Rep*. 2017;7(1):16956.